| Literature DB >> 29582626 |
Katsuya Watanabe1,2, Kentaro Sakamaki, Teppei Nishii, Taketsugu Yamamoto, Takamitsu Maehara, Haruhiko Nakayama, Munetaka Masuda.
Abstract
Objective: This study was designed to visually represent postoperative recurrence patterns using event dynamics and to assess sex-based differences in the timing of recurrence for non-small cell lung cancer.Entities:
Keywords: Gender; non-small cell cancer; recurrence; event dynamics
Mesh:
Year: 2018 PMID: 29582626 PMCID: PMC5980847 DOI: 10.22034/APJCP.2018.19.3.719
Source DB: PubMed Journal: Asian Pac J Cancer Prev ISSN: 1513-7368
Patient, Treatment, and Tumor Characteristics (n=829)
| Characteristic | Male | Female | p value |
|---|---|---|---|
| (n=538) | (n=291) | ||
| Age, years | 0.169 | ||
| Mean | 67.7±9.3 | 66.7±9.9 | |
| Histology | <0.001 | ||
| Adenocarcinoma | 273 (51%) | 245 (84%) | |
| Squamous cell | 178 (33%) | 30 (10%) | |
| Others | 87 (16%) | 16 (6%) | |
| Surgical procedure | 0.237 | ||
| Segmentectomy | 57 (11%) | 23 (8%) | |
| Lobectomy | 453 (84%) | 259 (89%) | |
| Bi-lobectomy | 6 (1%) | 3 (1%) | |
| Pneumonectomy | 22 (4%) | 6 (2%) | |
| Pathological stage | <0.001 | ||
| IA | 218 (41%) | 174 (60%) | |
| IB | 151 (28%) | 60 (20%) | |
| IIA | 19 (4%) | 6 (2%) | |
| IIB | 63 (12%) | 10 (3%) | |
| IIIA | 63 (12%) | 31 (10%) | |
| IIIB | 24 (5%) | 10 (3%) | |
| Smoking status | <0.001 | ||
| Current smoker/ ex-smoker | 483 (90%) | 95 (33%) | |
| Nonsmoker | 36 (7%) | 175 (60%) | |
| NOS | 19(4%) | 21(7%) | |
| Adjuvant chemotherapy | 0.003 | ||
| Yes | 147 (27%) | 53 (18%) | |
| No/ NOS | 391 (73%) | 238 (82%) |
NSCLC, non-small cell lung cancer; NOS, not otherwise specified
Figure 1(a) Disease-free survival curves according to sex ; (b) Smoothed hazard rate estimates for first event according to sex
Figure 2(a) Smoothed hazard rate estimates for first event according to pathological stage; (b) Smoothed hazard rate estimates for first event by sex in pathological stage: Stage IA; (c) Smoothed hazard rate estimates for first event by sex in pathological stage: Stage IB; (d) Smoothed hazard rate estimates for first event by sex in pathological stage: Stage IIA to IIIB
Figure 3(a) Smoothed hazard rate estimates for first event by sex in histology: Squamous cell carcinoma; (b) Smoothed hazard rate estimates for first event by sex in histology: Adenocarcinoma
Figure 4Smoothed Hazard Rate Estimates for First Event by Sex in Smokers